Rhumbline Advisers Purchases 691 Shares of Korro Bio, Inc. (NASDAQ:KRRO)

Rhumbline Advisers lifted its position in Korro Bio, Inc. (NASDAQ:KRRO) by 7.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,602 shares of the company’s stock after buying an additional 691 shares during the period. Rhumbline Advisers owned about 0.10% of Korro Bio worth $366,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Quest Partners LLC grew its stake in Korro Bio by 172.1% in the third quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock valued at $59,000 after acquiring an additional 1,124 shares during the period. Brown Brothers Harriman & Co. grew its position in shares of Korro Bio by 251.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 2,854 shares of the company’s stock valued at $95,000 after purchasing an additional 2,041 shares during the period. Vestcor Inc bought a new stake in Korro Bio during the 3rd quarter worth approximately $100,000. MetLife Investment Management LLC raised its holdings in Korro Bio by 129.0% during the 3rd quarter. MetLife Investment Management LLC now owns 3,639 shares of the company’s stock worth $122,000 after buying an additional 2,050 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in Korro Bio by 1,018.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,909 shares of the company’s stock worth $164,000 after buying an additional 4,470 shares during the period. Institutional investors and hedge funds own 13.18% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. William Blair reiterated an “outperform” rating on shares of Korro Bio in a report on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and issued a $115.00 target price on shares of Korro Bio in a research note on Friday, November 22nd. Finally, Oppenheimer assumed coverage on Korro Bio in a report on Friday, January 10th. They set an “outperform” rating and a $155.00 target price for the company. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $144.00.

Korro Bio Stock Up 0.6 %

Korro Bio stock opened at $22.33 on Monday. The company has a fifty day simple moving average of $33.01 and a 200 day simple moving average of $43.04. Korro Bio, Inc. has a 1-year low of $20.34 and a 1-year high of $98.00.

Korro Bio Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).